Clinical Drug Investigation

, Volume 34, Issue 2, pp 159–161

Tocilizumab Monotherapy in a Patient with Rheumatoid Arthritis and Iatrogenic Kaposi Sarcoma

  • Francesca Ingegnoli
  • Athanasia Tourlaki
  • Roberta Gualtierotti
Case Report

DOI: 10.1007/s40261-013-0159-9

Cite this article as:
Ingegnoli, F., Tourlaki, A. & Gualtierotti, R. Clin Drug Investig (2014) 34: 159. doi:10.1007/s40261-013-0159-9

Abstract

Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Francesca Ingegnoli
    • 1
  • Athanasia Tourlaki
    • 2
  • Roberta Gualtierotti
    • 1
  1. 1.Division of Rheumatology, Istituto Gaetano Pini, Department of Clinical Sciences and Community HealthUniversity of MilanoMilanItaly
  2. 2.Dermatology UnitFondazione IRCCS Ca’ Granda, Ospedale Maggiore PoliclinicoMilanItaly

Personalised recommendations